{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:30:24Z","timestamp":1762867824832},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10637-019-00817-0","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:02:30Z","timestamp":1561334550000},"page":"1239-1246","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component"],"prefix":"10.1007","volume":"37","author":[{"given":"Inkeun","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Kyoon","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinkyo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"key":"817_CR1","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/1097-0142(19870915)60:6<1313::AID-CNCR2820600625>3.0.CO;2-1","volume":"60","author":"A Sella","year":"1987","unstructured":"Sella A, Logothetis CJ, Ro JY, Swanson DA, Samuels ML (1987) Sarcomatoid renal cell carcinoma. A treatable entity. Cancer 60:1313\u20131318","journal-title":"Cancer"},{"key":"817_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1200\/JCO.1999.17.2.523","volume":"17","author":"T Cangiano","year":"1999","unstructured":"Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A (1999) Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17:523\u2013528","journal-title":"J Clin Oncol"},{"key":"817_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/cncr.24768","volume":"116","author":"B Shuch","year":"2010","unstructured":"Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ (2010) Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer 116:616\u2013624. https:\/\/doi.org\/10.1002\/cncr.24768","journal-title":"Cancer"},{"key":"817_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cll.2005.01.013","volume":"25","author":"CM Lohse","year":"2005","unstructured":"Lohse CM, Cheville JC (2005) A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 25:433\u2013464. https:\/\/doi.org\/10.1016\/j.cll.2005.01.013","journal-title":"Clin Lab Med"},{"key":"817_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2008.18.0000","volume":"27","author":"AR Golshayan","year":"2009","unstructured":"Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 27:235\u2013241. https:\/\/doi.org\/10.1200\/JCO.2008.18.0000","journal-title":"J Clin Oncol"},{"key":"817_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1023\/A:1008352024762","volume":"12","author":"N Bangalore","year":"2001","unstructured":"Bangalore N, Bhargava P, Hawkins MJ, Bhargava P (2001) Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol 12:271\u2013274","journal-title":"Ann Oncol"},{"key":"817_CR7","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s12032-010-9649-2","volume":"28","author":"JP Dutcher","year":"2011","unstructured":"Dutcher JP, Nanus D (2011) Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 28:1530\u20131533. https:\/\/doi.org\/10.1007\/s12032-010-9649-2","journal-title":"Med Oncol"},{"key":"817_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/CAD.0b013e3282f5d336","volume":"19","author":"Y Fujiwara","year":"2008","unstructured":"Fujiwara Y, Kiura K, Tabata M, Takigawa N, Hotta K, Umemura S, Omori M, Gemba K, Ueoka H, Tanimoto M (2008) Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anti-Cancer Drugs 19:431\u2013433. https:\/\/doi.org\/10.1097\/CAD.0b013e3282f5d336","journal-title":"Anti-Cancer Drugs"},{"key":"817_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/cncr.20541","volume":"101","author":"DM Nanus","year":"2004","unstructured":"Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP (2004) Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101:1545\u20131551. https:\/\/doi.org\/10.1002\/cncr.20541","journal-title":"Cancer"},{"key":"817_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/01.ju.0000026902.77397.fd","volume":"168","author":"B Escudier","year":"2002","unstructured":"Escudier B, Droz JP, Rolland F, Terrier-Lacombe MJ, Gravis G, Beuzeboc P, Chauvet B, Chevreau C, Eymard JC, Lesimple T, Merrouche Y, Oudard S, Priou F, Guillemare C, Gourgou S, Culine S, Genitourinary Group of the French Federation of Cancer C (2002) Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol 168:959\u2013961. https:\/\/doi.org\/10.1097\/01.ju.0000026902.77397.fd","journal-title":"J Urol"},{"key":"817_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s12032-011-9829-8","volume":"29","author":"NB Haas","year":"2011","unstructured":"Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J (2011) A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 29:761\u2013767. https:\/\/doi.org\/10.1007\/s12032-011-9829-8","journal-title":"Med Oncol"},{"key":"817_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00432-013-1386-4","volume":"139","author":"I Park","year":"2013","unstructured":"Park I, Cho YM, Lee JL, Ahn JH, Lee DH, Song C, Hong JH, Kim CS, Ahn H (2013) Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component. J Cancer Res Clin Oncol 139:817\u2013827. https:\/\/doi.org\/10.1007\/s00432-013-1386-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"817_CR13","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/j.clgc.2014.04.004","volume":"12","author":"B Beuselinck","year":"2014","unstructured":"Beuselinck B, Lerut E, Wolter P, Dumez H, Berkers J, Van Poppel H, Joniau S, Oyen R, De Wever L, Strijbos M, Paridaens R, Schoffski P (2014) Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. Clin Genitourin Cancer 12:e205\u2013e214. https:\/\/doi.org\/10.1016\/j.clgc.2014.04.004","journal-title":"Clin Genitourin Cancer"},{"key":"817_CR14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/COC.0b013e3181f47aa4","volume":"34","author":"AM Molina","year":"2011","unstructured":"Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ (2011) Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 34:454\u2013459. https:\/\/doi.org\/10.1097\/COC.0b013e3181f47aa4","journal-title":"Am J Clin Oncol"},{"key":"817_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.clgc.2013.12.001","volume":"12","author":"V Kunene","year":"2014","unstructured":"Kunene V, Miscoria M, Pirrie S, Islam MR, Afshar MPorfiri E (2014) Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib. Clin Genitourin Cancer 12:251\u2013255. https:\/\/doi.org\/10.1016\/j.clgc.2013.12.001","journal-title":"Clin Genitourin Cancer"},{"key":"817_CR16","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/j.clgc.2014.08.011","volume":"13","author":"CE Kyriakopoulos","year":"2015","unstructured":"Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2015) Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 13:e79\u2013e85. https:\/\/doi.org\/10.1016\/j.clgc.2014.08.011","journal-title":"Clin Genitourin Cancer"},{"key":"817_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/2047-783X-15-7-287","volume":"15","author":"M Staehler","year":"2010","unstructured":"Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, Karl A, Stief CG (2010) Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res 15:287\u2013291","journal-title":"Eur J Med Res"},{"key":"817_CR18","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1002\/cncr.29503","volume":"121","author":"MD Michaelson","year":"2015","unstructured":"Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK (2015) Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and\/or poor-risk metastatic renal cell carcinoma. Cancer 121:3435\u20133443. https:\/\/doi.org\/10.1002\/cncr.29503","journal-title":"Cancer"},{"key":"817_CR19","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272\u20137283. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0652","journal-title":"Clin Cancer Res"},{"key":"817_CR20","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(11)61613-9","journal-title":"Lancet"},{"key":"817_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12032-018-1231-3","volume":"36","author":"S Konishi","year":"2018","unstructured":"Konishi S, Hatakeyama S, Tanaka T, Ikehata Y, Tanaka T, Fujita N, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Kawaguchi T, Masumori N, Kitamura H, Ohyama C (2018) Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis. Med Oncol 36:6. https:\/\/doi.org\/10.1007\/s12032-018-1231-3","journal-title":"Med Oncol"},{"key":"817_CR22","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1016\/j.clgc.2018.05.011","volume":"16","author":"I Park","year":"2018","unstructured":"Park I, Lee SH, Lee JL (2018) A multicenter phase II trial of Axitinib in patients with recurrent or metastatic non-clear-cell renal cell carcinoma who had failed prior treatment with Temsirolimus. Clin Genitourin Cancer 16:e997\u2013e1002. https:\/\/doi.org\/10.1016\/j.clgc.2018.05.011","journal-title":"Clin Genitourin Cancer"},{"key":"817_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/s1470-2045(11)70004-3","volume":"12","author":"HL Kindler","year":"2011","unstructured":"Kindler HL, Ioka T, Richel DJ, Bennouna J, L\u00e9tourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E (2011) Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12:256\u2013262. https:\/\/doi.org\/10.1016\/s1470-2045(11)70004-3","journal-title":"Lancet Oncol"},{"key":"817_CR24","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.clgc.2017.07.028","volume":"16","author":"A Maiti","year":"2017","unstructured":"Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY (2017) Phase 2 trial of Capecitabine, gemcitabine, and bevacizumab in Sarcomatoid renal-cell carcinoma. Clin Genitourin Cancerdoi 16:e47\u2013e57. https:\/\/doi.org\/10.1016\/j.clgc.2017.07.028","journal-title":"Clin Genitourin Cancerdoi"},{"key":"817_CR25","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422\u20135428. https:\/\/doi.org\/10.1200\/JCO.2008.16.9847","journal-title":"J Clin Oncol"},{"key":"817_CR26","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, Investigators AT (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103\u20132111. https:\/\/doi.org\/10.1016\/S0140-6736(07)61904-7","journal-title":"Lancet"},{"key":"817_CR27","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","volume":"14","author":"TE Hutson","year":"2013","unstructured":"Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ (2013) Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 14:1287\u20131294. https:\/\/doi.org\/10.1016\/S1470-2045(13)70465-0","journal-title":"Lancet Oncol"},{"key":"817_CR28","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","volume":"3","author":"RW Joseph","year":"2015","unstructured":"Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, Bryce AH, Vogelzang NJ, Stanton ML, Castle EP, Ho TH (2015) PD-1 and PD-L1 expression in renal cell carcinoma with Sarcomatoid differentiation. Cancer Immunol Res 3:1303\u20131307. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0150","journal-title":"Cancer Immunol Res"},{"key":"817_CR29","doi-asserted-by":"publisher","first-page":"mdy424.037","DOI":"10.1093\/annonc\/mdy424.037","volume":"29","author":"BI Rini","year":"2018","unstructured":"Rini BI, Huseni M, Atkins MB, McDermott DF, Powles TB, Escudier B, Banchereau R, Liu LF, Leng N, Fan J, Doss J, Nalle S, Carroll S, Li S, Schiff C, Green M, Motzer RJ (2018) LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). Ann Oncol 29:mdy424.037\u2013mdy424.037. https:\/\/doi.org\/10.1093\/annonc\/mdy424.037","journal-title":"Ann Oncol"},{"key":"817_CR30","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1073\/pnas.1525735113","volume":"113","author":"M Bi","year":"2016","unstructured":"Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilguvar K, Lifton RP, Shuch B (2016) Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A 113:2170\u20132175. https:\/\/doi.org\/10.1073\/pnas.1525735113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"817_CR31","doi-asserted-by":"publisher","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-17-1057","volume":"23","author":"Z Wang","year":"2017","unstructured":"Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K (2017) Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape. Clin Cancer Res 23:6686\u20136696. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1057","journal-title":"Clin Cancer Res"},{"key":"817_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JOP.18.00213","volume":"14","author":"N El Mouallem","year":"2018","unstructured":"El Mouallem N, Smith SC, Paul AK (2018) Complete response of a patient with metastatic Sarcomatoid renal cell carcinoma to a programmed Death-1 checkpoint inhibitor. J Oncol Pract 14:511\u2013513. https:\/\/doi.org\/10.1200\/JOP.18.00213","journal-title":"J Oncol Pract"},{"key":"817_CR33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.eururo.2015.07.008","volume":"68","author":"DM Geynisman","year":"2015","unstructured":"Geynisman DM (2015) Anti-programmed cell death protein 1 (PD-1) antibody Nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with Sarcomatoid and Rhabdoid features. Eur Urol 68:912\u2013914. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.008","journal-title":"Eur Urol"},{"key":"817_CR34","doi-asserted-by":"publisher","first-page":"e1127","DOI":"10.1016\/j.clgc.2017.05.028","volume":"15","author":"K Rouvinov","year":"2017","unstructured":"Rouvinov K, Osyntsov L, Shaco-Levy R, Baram N, Ariad S, Mermershtain W (2017) Rapid response to Nivolumab in a patient with Sarcomatoid transformation of Chromophobe renal cell carcinoma. Clin Genitourin Cancer 15:e1127\u2013e1130. https:\/\/doi.org\/10.1016\/j.clgc.2017.05.028","journal-title":"Clin Genitourin Cancer"},{"key":"817_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","volume":"34","author":"DF McDermott","year":"2016","unstructured":"McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fasso M, Wang YV, Zou W, Hegde PS, Fine GD, Powles T (2016) Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34:833\u2013842. https:\/\/doi.org\/10.1200\/JCO.2015.63.7421","journal-title":"J Clin Oncol"},{"key":"817_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.eururo.2016.01.051","volume":"70","author":"GG Malouf","year":"2016","unstructured":"Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA (2016) Genomic characterization of renal cell carcinoma with Sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. Eur Urol 70:348\u2013357. https:\/\/doi.org\/10.1016\/j.eururo.2016.01.051","journal-title":"Eur Urol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00817-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00817-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00817-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:39:59Z","timestamp":1678559999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00817-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00817-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,24]]},"assertion":[{"value":"18 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethical standards"}},{"value":"Inkeun Park received honoraria for consulting or advisory roles from Pfizer Korea, Eisai Korea, Bristol-Myers Squibb pharma Korea, Astellas Pharma Korea, Janssen Korea, and iPSEN Korea. Jae Lyun Lee received honoraria for consulting or advisory roles from Pfizer Korea, Eisai Korea, Sanofi-Aventis Korea, Bristol-Myers Squibb Korea, Astellas Pharma, and Amgen Korea, and his institution received research funds from Pfizer, grants from Janssen, grants from Novartis, grants from Bristol-Myers Squibb, grants from Reche\/Genentech, grants from AstraZeneca\/MedImmune, grants from MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was approved by the institutional review board of each participating centers and Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}